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Protocol
AbstrACt
Introduction Trigeminal neuralgia (TN) affects 4 to 
28.9/100 000 people worldwide, and antiepileptic drugs 
such as carbamazepine and oxcarbazepine are the firstline 
treatment options. However, the efficacy and safety of 
other antiepileptic drugs remain unclear due to insufficient 
direct comparisons.
Objective To compare the efficacy and acceptability of all 
currently available antiepileptic agents for the treatment of 
patients with classical TN.
Methods We will search the PubMed, EMBASE, Cochrane 
Library and Web of Science databases for unpublished 
or undergoing research listed in registry platforms. We 
will include all randomised controlled trials comparing 
two different antiepileptic drugs or one antiepileptic drug 
with placebo in patients with classical TN. The primary 
outcomes will be the proportion of responders and the 
number of subjects who dropout during the treatment. 
The secondary outcomes will include the two primary 
outcomes but in the follow-up period, changes in the self-
reporting assessment scale for neuralgia and quality of life 
assessment. In terms of network meta-analysis, we will fit 
our model to a Bayesian framework using the JAGS and 
pcnetmeta packages of the R project.
Ethics and dissemination This protocol will not 
disseminate any private patient data. The results of 
this review will be disseminated through peer reviewed 
publication.
PrOsPErO registration number CRD42016048640.
IntrOduCtIOn  
Classical trigeminal neuralgia (TN), a 
chronic pain disorder described as one of 
the most severe pains one can suffer, is char-
acterised by paroxysms of unilateral, electric 
shock-like severe pain along the trigeminal 
nerve divisions.1 2 It affects lifestyle because it 
can be triggered by common activities, such 
as eating, talking, shaving or brushing your 
teeth. The wind, chewing and talking also 
aggravate the condition in many patients.2 It 
is estimated that approximately 4 to 28.9 per 
100 000 people worldwide suffer from TN, 
and the number affected tends to be higher 
among women at all ages and even increases 
with age.3 4 
At present, the cause of TN remains 
unclear.5 6 One hypotheses is that the trigem-
inal nerve becomes compressed at the root 
entry zone by cerebral vessels.7 Owing to the 
contradictory aetiology and poorly under-
stood pathophysiological mechanisms under-
lying TN, a variety of therapeutic and surgical 
approaches have been developed to alleviate 
the associated pain and improve the quality of 
life for patients with classical TN.8–10 Although 
many patients have obtained excellent 
outcomes from surgery, many others do not 
experience any pain relief.11 12 Furthermore, 
the currently available surgical procedures 
are associated with various complications, 
particularly sensory loss in the trigeminal 
nerve territory, anaesthesia dolorosa and, 
rarely, ipsilateral hearing loss, depending on 
the technique.13 14
Hence pharmacological measures to 
improve clinical outcomes are needed. The 
most commonly used option is antiepileptic 
drugs, with phenytoin being the first drug 
to be used for classical TN with a positive 
effect.15 Carbamazepine can reduce both the 
frequency and intensity of painful paroxysms 
and was first introduced by the US Food and 
strengths and limitations of this study
 ► To the best of the authors’ knowledge, this study 
will be the first network meta-analysis to assess 
the comparative efficacy and acceptability of all the 
available antiepileptic drugs for the treatment of 
classical trigeminal neuralgia.
 ► This study will be performed by Bayesian framework, 
which will enable us to estimate the probability of 
each intervention to be the best for each outcome.
 ► Owing to language barriers, the number of included 
trials may be potentially limited.
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Drug Administration; however, its efficacy is compro-
mised by poor tolerability.16 Oxcarbazepine, a derivative 
of carbamazepine, is often used as an initial treatment 
for classical TN and has more favourable properties 
than carbamazepine related to its increased efficacy in 
epilepsy, greater tolerability and decreased potential for 
drug interactions.17 Lamotrigine has also been reported 
as an effective add-on therapy,18 whereas there is little 
evidence that other antiepileptic drugs, such as clonaz-
epam, gabapentin, pregabalin and valproate, have a bene-
ficial effect.19–22 However, many of the studies are old with 
limited methodology, and were assessed as having low 
Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) scores.23
To date, several systematic reviews have investigated 
the comparative efficacy and safety of antiepileptic 
drugs.20 24–28 However, previous systematic reviews have 
only considered pairwise evidence from head to head 
comparisons and have thus failed to assess the compar-
ative efficacy and acceptability of all the available antie-
pileptic drugs. Thus it is difficult to determine the best 
treatments for relieving pain with minimal adverse effects. 
In the present study, we choose a group of nine antie-
pileptic drugs, looking at drugs which were licensed for 
neuralgia in many countries and which were frequently 
used in clinical practice. We will apply network meta-anal-
ysis to integrate direct and indirect comparisons,29 30 
which could be used not only to strengthen inferences 
concerning the efficacy and acceptability of treatments 
but also to rank the efficacy and acceptability of antiepi-
leptic drugs accordingly.31
The objectives of this systematic review and network 
meta-analysis are: (1) to compare all currently available 
antiepileptic drugs in terms of efficacy and acceptability 
in the treatment of classical TN; and (2) to determine 
which drug achieves the best balance between efficacy 
and adverse effects. The results of this study will augment 
findings based on current pairwise meta-analyses and are 
expected to provide important information to support 
clinical practice and health policy decisions.
MEthOds
This protocol will be conducted in accordance with the 
reporting guidance provided in the Preferred Reporting 
Items for Systematic Reviews and Meta-Analysis Protocols 
(PRISMA-P) statement and Checklist of Items to Include 
When Reporting a Systematic Review Involving a Network 
Meta-analysis.32 33 The protocol is registered in PROS-
PERO (CRD: 42016048640). This study will not involve 
any private patient data; ethics approval was waived (see 
online supplementary file 1 for PRISMA-P checklist).
Eligibility criteria
Study types
We will include randomised controlled trials (RCTs) 
comparing one antiepileptic drug with another antiepi-
leptic drug as monotherapy or placebo for the treatment 
of TN. Quasi-randomised controlled trails allocating 
participants according to birth date or the consequences 
of enrolment will be excluded. The minimum duration 
for RCT inclusion will be set at 4 weeks. Trials with more 
than a two arm design will be considered only if the avail-
able data meet the criteria for an intervention. For trials 
with a crossover design, data will only be extracted from 
the first randomisation period.
Participant characteristics
Only trials that enrolled participants with a diagnosis of 
classical TN according to standardised criteria, such as 
the International Headache Society’s classification, Inter-
national Classification of Headache Disorders, will be 
sought.1 34 For studies using other extensive criteria for 
the diagnosis of classical TN, detailed diagnostic criteria 
must be reported (such as history or characteristics that 
have been confirmed by CT or MRI).35 Studies examining 
symptomatic TN patients will not be included. Partici-
pants with comorbid conditions, such as anxiety, depres-
sion, epilepsy or other medical conditions, will not be 
eligible for inclusion. No limitations will be imposed on 
age, sex or nationality.
Intervention types
We plan to include the following antiepileptic drugs: 
carbamazepine, lamotrigine, clonazepam, phenytoin, 
valproate, gabapentin, pregabalin, oxcarbazepine and 
topiramate. In addition to these antiepileptic drugs, 
we will also obtain information about interventions of 
interest from either pairwise RCTs or placebo controlled 
trails, as some RCTs design a placebo controlled arm 
as the comparator. Figure 1 illustrates the network plot 
of all possible direct comparisons between the eligible 
interventions.
Outcome measures
Studies reporting one of the following will be included.
Primary outcomes
The primary objective of this review is to assess the effi-
cacy and acceptability of antiepileptic drugs for classical 
TN; therefore, the following two outcomes will be used as 
the primary outcomes.
1. The proportion of responders to a self-reporting 
assessment scale for neuralgia. A responder was de-
fined as a subject who obtained ≥50% reduction in 
pain score from baseline to the study endpoint (4–12 
weeks) or a subject who obtained a pain reducing 
score of no less than the minimal clinically important 
difference. Pain scores will be extracted based on the 
visual analogue score, numerical rating score or any 
other validated scale for the assessment of overall TN 
symptoms when available.36
2. Treatment acceptability is defined as the proportion 
of patients who have intervention related adverse 
events during the 4–12 weeks.
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Secondary outcomes
1. The proportion of responders with ≥50% pain reduc-
tion on a self-reporting assessment scale for neuralgia 
from baseline to the endpoint after follow-up.
2. The change in pain symptoms of TN from baseline to 
the endpoint (4–12 weeks), based on the visual ana-
logue score, numerical rating score or any other vali-
dated scale for the assessment of overall TN symptoms 
when available.
3. The change in pain symptoms of TN from baseline to 
the endpoint after follow-up.
4. The quality of life based on measurement with a vali-
dated scale, such as the Short Form 36 Health Survey 
questionnaire.37
search strategy
We will identify RCTs through a comprehensive, system-
atic literature search, primarily utilising the PubMed, 
EMBASE, Cochrane Library and Web of Science data-
bases. As publication bias caused by insufficient unpub-
lished data can significantly bias the comparative efficacy 
results of network meta-analyses and modify rankings, we 
will also perform searches for unpublished or ongoing 
trials using the System for information on Grey Literature 
in Europe (SIGLE) as well as other registry platforms, 
such as  Clinicaltrials. gov and the International Clinical 
Trials Registry Platform. Prior to completing this review, 
we will perform an additional search of each database and 
registration platform to guarantee that the most recent 
studies are included. We will use medical subject head-
ings and text words related to ‘trigeminal neuralgia’ and 
‘randomised controlled trial’ for the literature search. In 
addition, the reference lists of previous systematic reviews 
will be examined to ensure the quantity and accuracy of 
the included studies. The search strategy will be devel-
oped by JT and ZL; we anticipate that the databases will 
be searched from their inception to 30 September 2017 
(see online supplementary file 2 for the search strategies 
for PubMed, EMBASE and Cochrane Library).
data collection process
Two authors (SX and ZM) will scan the titles and abstracts 
of the trials after duplicated records have been excluded 
using EndNote X7 (Thomson Reuters, New York, New 
York, USA). The scanning will be performed using 
EndNote, and all trials will be allocated to the following 
five groups: inclusion group, non-patient group, inter-
vention group, outcome group and awaiting group. A 
prior data collection process will be conducted using an 
electro table created with Excel software, which has been 
used in our previous study.38 The table will consist of four 
sheets, including general information (author list, publi-
cation year and journal), characteristics of the included 
trials (diagnostic criteria, age range, study drugs and dose 
range), risk of bias assessed using the Cochrane risk of 
bias tool and outcome data extraction (number of partic-
ipants who responded to treatment and the number who 
dropped out during the treatment). All original data will 
be submitted as an attachment. A flowchart illustrating 
this design is presented in figure 2.
Quality assessment
Two authors (JW and YL) will use the Cochrane risk of 
bias tool to assess the risk of bias of the eligible studies, 
Figure 1 Network plot of all possible direct comparisons between the eligible interventions.
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covering randomisation, concealment allocation, 
blinding and other biases.39 As inadequate conceal-
ment could potentially fail the randomisation test, two 
independent review authors will pay particular atten-
tion to the adequacy of random allocation concealment 
and blinding. The other sources of bias will be assessed 
considering the sample size calculation method, diag-
nostic criteria, reporting of withdrawals and follow-up. 
Two authors (JSWK and JT) will assess the quality of 
evidence using the GRADE framework, covering study 
limitations, inconsistency, indirectness, imprecision and 
publication bias.40 The methods for rating the quality of 
direct comparisons are the same as the methods used in 
traditional meta-analyses, and the following steps will be 
used in the whole assessment procedure: (1) presenting 
direct and indirect effect estimates; (2) rating the quality 
of direct and indirect estimates; (3) presenting the results 
of the network meta-analysis; and (4) rating the quality of 
the network meta-analysis effect estimates.
dealing with missing data
To obtain missing data, we will initially contact the senior 
or corresponding author. If no one responds, we will 
estimate the missing data as follows. For studies failing 
to report the number of responding patients after treat-
ment, instead of providing the mean and SD, we will 
calculate the number of responding patients employing 
a validated imputation method.41 In addition, we will also 
estimate missing data from graphs when possible. For 
trials that cannot be extracted or estimated, the available 
data will be excluded, and the reason for exclusion will 
be reported.
statistical analysis
The method used for data synthesis will be based on 
mixed treatment meta-analysis. To examine compari-
sons, we will use Stata (13.0; Stata Corporation, College 
Station, Texas, USA) to synthesise data and will present 
the comparison results if the included studies are 
sufficient for each pairwise comparison. We will use a 
random effects model to combine the data, and the 
outcomes of continuous and binary variables will be 
presented as standardised mean differences (SMDs) 
and ORs with 95% CIs. For indirect comparisons, we 
will perform an arm based network meta-analysis for all 
treatments using a random effects model with a Bayesian 
framework using the pcnetmeta package of the R 
project, which can conduct calculations using JAGS soft-
ware.42–44 This will enable us to estimate the best prob-
ability of each intervention for each positive outcome, 
given the results of the multiple treatment meta-anal-
ysis. At least one network focusing on the response rate 
for pain relief will be constructed, in which a statistically 
significant difference defined as the null value will not 
Figure 2 PRISMA flowchart. RCT, randomised controlled trial.
 5Qin Z, et al. BMJ Open 2018;8:e017392. doi:10.1136/bmjopen-2017-017392
Open Access
be included in the 95% CI. All models will be utilised 
for 50 000 simultaneous iterations based on the data 
and the description of the proposed distributions for 
relevant parameters, and the first 10 000 iterations will 
be discarded to avoid potential impact on the arbitrary 
value. For continuous outcomes and binary outcomes, 
the OR and SMD values will be presented with the 
95% credible interval (CrI).
To describe relationships among different treatments, 
a network plot will be created to show direct compari-
sons between arms based on different outcomes.42 In 
addition, the effectiveness of each treatment among all 
available treatments will be ranked by calculating the 
OR in order, and plots of the treatment rank probabil-
ities will be generated to rank the various treatments 
for each outcome using the functions in package pcnet-
meta.42 43 We will also present a cluster rank table to 
synthesise the efficacy and acceptability of each drug 
(using two primary outcomes). The table will consist of 
two triangles: the upper right triangle will illustrate the 
acceptability and the lower left triangle will illustrate 
the efficacy.31 For pairwise meta-analyses we will use 
Stata 13.0. For network meta-analyses we will use JAGS 
and R project.
Assessment of heterogeneity
Heterogeneity, which plays a pivotal role in both standard 
meta-analyses and network meta-analyses, refers to the 
degree of disagreement between study specific treatment 
effects and constitutes the basis of inconsistency. To test 
the heterogeneity of each pairwise comparison, we will 
use the I² statistic.45
Assessment of transitivity and similarity
In addition to the heterogeneity assessment using the 
I² statistic, the assumption of transitivity and similarity 
based on clinical and methodological characteristics 
will be assessed. It should be noted that it is difficult to 
identify these effect modifiers using statistical analysis. 
We will assume that intervention effects are transitive 
in this network meta-analysis because we will only focus 
on antiepileptic drugs, and we will investigate similarity 
based on clinical characteristics, such as antiepileptic 
drug dose, period of treatment and severity of pain symp-
toms at baseline, as well as according to methodological 
characteristics, such as study quality.46 All of these effect 
modifiers will be judged and reported before the network 
meta-analysis is conducted.
Assessment of inconsistency
Evaluation and explanation of inconsistency is another 
basic objective of a network meta-analysis. In this context, 
inconsistency refers to the degree of difference between 
direct and indirect comparisons and can be evaluated only 
when a loop exists in the evidence network. This means 
that inconsistency assessment using a design by treatment 
interaction model cannot be conducted if the structure of 
this network is a ‘star network’ (ie, all interventions have 
a single mutual comparator, such as a placebo).47 48 For 
such cases, we will test inconsistency using a node split-
ting model.49
To identify inconsistency among the included trials of 
the network, we will use Stata, performing the Z test to 
compare direct and indirect summary effects in specific 
loops.50 If there is no inconsistency between loops or 
designs, we will use a consistency model to calculate 
the data. For cases of significant incoherence, we will 
initially look for data extraction errors in loops that 
present inconsistency and in comparisons with large 
heterogeneity.51 After the data have been scrutinised, we 
will investigate possible sources of inconsistency within 
the clinical and methodological variables suspected of 
being potential sources of either heterogeneity or inco-
herence in each comparison specific group of trials. If 
an important inconsistency cannot be explained, we will 
consider avoiding synthesis of the related network.
Additional analyses
To ensure the quality of this review, studies not reporting 
blinding will be excluded prior to data synthesis because 
blinding plays a vital important role in the RCT. We will 
assess heterogeneity quantitatively using the I² statistic, 
and if an I2 value is >50%, we will explore the source of 
heterogeneity. We will initially perform sensitivity anal-
ysis by excluding trials rated as having a high risk of bias. 
Additionally, meta-regression or subgroup analysis will 
be used to explore possible sources of heterogeneity if 
the number of included trials is sufficient. For network 
meta-regression, we will use a random effects network 
meta-regression model to examine potential factors.
dIsCussIOn
To the best of our knowledge, no network meta-anal-
yses comparing the use of antiepileptic drugs for the 
treatment of classical TN have been conducted to date. 
Previous systematic reviews have compared only a single 
drug to other types of drug or therapy.20 24–28 This makes 
it difficult to obtain a clear understanding of the effec-
tiveness of the various different conservative treatments 
for this disorder. A network meta-analysis can be used 
to perform indirect comparisons and allows parameters 
for direct and indirect comparisons to be synthesised. 
To ensure the quantity and quality of the potentially 
included RCTs, we will perform an extensive literature 
search and predefine rigorous inclusion criteria. Also, 
we will assess the quality of evidence using the GRADE 
framework. Although a ranking of the included inter-
ventions will be generated, with the exception of find-
ings, the quality of evidence should also be considered. 
We hope that the results of this review will help clini-
cians make more accurate treatment decisions and 
promote additional research into conservative treat-
ments for classical TN.
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Amendments
If it is necessary we will update this protocol in the future. 
We will submit the original protocol, final protocol and 
summary of changes as a supplement.
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